The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Interim analysis of a Phase II trial of epcoritamab plus lenalidomide in treatment-naive FL
Swetha Thiruvengadam, MD, City of Hope, Duarte, CA, shares findings from the interim analysis of a Phase II investigator-initiated trial (NCT06112847) evaluating epcoritamab in combination with lenalidomide in treatment-naive follicular lymphoma (FL). Dr Thiruvengadam highlights that the combination showed high efficacy and a good safety profile, with longer follow-up needed to assess the durability of responses. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This actually presented the interim analysis of Phase II investigation trial, evaluating epcoritamab in combination with lenalidomide in treatment-naive follicular lymphoma. We had 27 patients enrolled to date, and this combination showed high efficacy and an overall good safety profile in patients with treatment-naive follicular lymphoma. In the 27 patients, of them 22 were response-evaluable at this time, and all patients except one achieved a complete response...
This actually presented the interim analysis of Phase II investigation trial, evaluating epcoritamab in combination with lenalidomide in treatment-naive follicular lymphoma. We had 27 patients enrolled to date, and this combination showed high efficacy and an overall good safety profile in patients with treatment-naive follicular lymphoma. In the 27 patients, of them 22 were response-evaluable at this time, and all patients except one achieved a complete response. At a median follow-up of 10 months, there have been no cases of progression or death. With respect to safety, the most frequent toxicities observed were cytokine release syndrome, GI toxicities, as well as cytopenias as expected. A majority of patients had low-grade cytokine release syndrome with a predominance of grade 1, and about half of the patients, 20%, had grade 2 cytokine release syndrome with an overall incidence of 70% in the cohort. Longer follow-up is needed to better assess the durability of responses with this combination in treatment-naive of follicular lymphoma.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
